Company Overview of AnaptysBio, Inc.
AnaptysBio, Inc. focuses on the generation of antibody therapeutics, as well as on the use of somatic hypermutation (SHM) for antibody discovery and optimization. The company’s SHM-XEL platform couples human antibody libraries with in vitro somatic hypermutation in mammalian cells to generate high affinity antibodies that replicates key features of the human immune system. It develops ANB020Its, an anti-IL-33 lead candidate antibody that inhibits IL-33 cytokine function by blocking interaction with receptor at low picomolar potency; a portfolio of antibodies for immuno-oncology to modulate the function of T cell negative regulators, including PD-1, TIM-3, and LAG-3; ANB012, an anti-ActRIIb a...
10421 Pacific Center Court
San Diego, CA 92121
Founded in 2005
Key Executives for AnaptysBio, Inc.
Chief Executive Officer, President and Director
Chief Development Officer
Compensation as of Fiscal Year 2015.
AnaptysBio, Inc. Key Developments
AnaptysBio Appoints Robert E. Hoffman as Chief Financial Officer
Jul 13 15
AnaptysBio, Inc. announced the appointment of Robert E. Hoffman as Chief Financial Officer. Mr. Hoffman joins the company after serving as Chief Financial Officer of Arena Pharmaceuticals, Inc. and Polaris Group. Prior to joining AnaptysBio, Mr. Hoffman was employed by Arena Pharmaceuticals, Inc. where since 1997 he served various roles with increasing responsibility leading to Senior Vice President, Finance and Chief Financial Officer since June 2012. Mr. Hoffman is a member of the board of directors of CombiMatrix Corporation, MabVax Therapeutics Holdings, Inc. and Kura Oncology, Inc. He also serves as a member of the Financial Accounting Standards Board's Small Business Advisory Committee and the steering committee of the Association of Bioscience Financial Officers.
AnaptysBio Announces Board Appointments
Jun 30 15
AnaptysBio, Inc. announced the appointment of Hollings Renton and John Schmid to its Board of Directors. Mr. Renton received a B.S. in Mathematics from Colorado State University and a M.B.A. from the University of Michigan. Mr. Schmid served as Chief Financial Officer of Auspex Pharmaceuticals, Inc. from September 2013 until its sale to Teva Pharmaceuticals, Inc. in June 2015.
AnaptysBio, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015
May 17 15
AnaptysBio, Inc. Presents at Sachs Immuno-Oncology: BD&L and Investment Forum, May-29-2015. Venue: Hyatt Chicago Magnificent Mile, Chicago, Illinois, United States. Presentation Date & Speakers: May-29-2015, Hamza Suria, Chief Executive Officer, President and Director.
Similar Private Companies By Industry
Recent Private Companies Transactions
July 13, 2015